Associations - Thyroid Gland Papillary Carcinoma

CANCER:

Thyroid Gland Papillary Carcinoma

Related cancers:

‹

Thyroid Gland Carcinoma (312)

Thyroid Gland Anaplastic Carcinoma (55)

Thyroid Gland Medullary Carcinoma (53)

Thyroid Gland Follicular Carcinoma (24)

Thyroid Gland Hurthle Cell Carcinoma (12)

Thyroid Gland Carcinoma (312)

Thyroid Gland Anaplastic Carcinoma (55)

Thyroid Gland Medullary Carcinoma (53)

Thyroid Gland Follicular Carcinoma (24)

Thyroid Gland Hurthle Cell Carcinoma (12)

›

No biomarker No biomarker	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker No biomarker	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
NTRK2 fusion NTRK2 fusion	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
No biomarker No biomarker	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	denosumab Sensitive: A2 - Guideline denosumab Sensitive : A2
RET fusion RET fusion	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
NTRK3 fusion NTRK3 fusion	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion NTRK2 fusion	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK1 fusion NTRK1 fusion	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK3 fusion NTRK3 fusion	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK1 fusion NTRK1 fusion	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
TMB-H TMB-H	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
RET fusion RET fusion	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2
BRAF V600E BRAF V600E	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	trametinib + dabrafenib Sensitive: C1 - Off-label trametinib + dabrafenib Sensitive : C1
BRAF V600E BRAF V600E	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1
BRAF mutation BRAF mutation	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	trametinib + dabrafenib Sensitive: C2 – Inclusion Criteria trametinib + dabrafenib Sensitive : C2
BRAF mutation BRAF mutation	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	PLX8394 + cobicistat Sensitive: C3 – Early Trials PLX8394 + cobicistat Sensitive : C3
BRAF V600 BRAF V600	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	BGB-283 Sensitive: C3 – Early Trials BGB-283 Sensitive : C3
BRAF mutation BRAF mutation	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	dabrafenib Sensitive: C3 – Early Trials dabrafenib Sensitive : C3
BRAF V600E BRAF V600E	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	siltuximab Sensitive: C4 – Case Studies siltuximab Sensitive : C4
PDGFRB overexpression PDGFRB overexpression	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4
EGFR overexpression EGFR overexpression	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4
BRAF V600 BRAF V600	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	dabrafenib + SNR1611 Sensitive: C4 – Case Studies dabrafenib + SNR1611 Sensitive : C4
NCOA4-RET fusion NCOA4-RET fusion	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	lenvatinib Sensitive: C4 – Case Studies lenvatinib Sensitive : C4
TPM3-NTRK1 fusion TPM3-NTRK1 fusion	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	AB106 Sensitive: C4 – Case Studies AB106 Sensitive : C4

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES